| About Jubilant Drug Discovery and Development services (JDDDS) |
Jubilant Drug Discovery and Development Services (JDDDS), is part of the Jubilant LifeSciences family of companies with R&D Centers in India, USA and business offices in Asia, Europe and North America. JDDDS has a global reach and provides comprehensive drug discovery and development solutions from target discovery to clinical development in partnership with leading pharma companies worldwide.
With clear scientific focus in Oncology, Metabolic Disorders, CNS and Pain and Inflammation, JDDDS has rapidly emerged as a leading collaborator for pharma industry. In each of these therapeutic areas, Jubilant has developed a depth of expertise in discovery informatics, medicinal chemistry, structural biology, biology, in vitro, in vivo models and translational sciences. Combined with strong clinical development and manufacturing capabilities, Jubilant has emerged as a fully integrated company with end-to-end solution for pharma industry.
JDDDS business constitutes three Jubilant subsidiaries, Jubilant Biosys (Drug discovery services), Jubilant Chemsys (Chemistry services) and Jubilant Clinsys (Clinical trial services). With over 1200 highly skilled and experienced scientific and medical personnel spread across Bangalore and Noida in India, Europe and the US, the JDDDS vertical leverages the capabilities in emerging markets for a global outcome, accelerating the global drug development efforts. |
|
|
|
| Latest News |
| 18-10-2011 |
| Norgine and Jubilant Announce Discovery Collaboration in Gastrointestinal Therapeutic Area. |
|
| Norgine, a leading European specialty pharmaceutical company and Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd, an integrated Pharma & life sciences company of India, announced today, that they have entered into a discovery partnership. The collaboration, spanning an initial period of 3 years will provide a platform for Norgine to develop multiple targets utilizing Jubilant Biosys integrated drug.... |
|
|
|
|
|
